Orthofix Medical (NASDAQ:OFIX) Earns “Sell (D-)” Rating from Weiss Ratings

Orthofix Medical (NASDAQ:OFIX)‘s stock had its “sell (d-)” rating reiterated by investment analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Several other equities analysts also recently issued reports on OFIX. Barrington Research reissued an “outperform” rating and issued a $17.00 target price on shares of Orthofix Medical in a research report on Thursday. Wall Street Zen raised shares of Orthofix Medical from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.75.

Orthofix Medical Stock Performance

Shares of NASDAQ:OFIX opened at $15.97 on Friday. The company has a market capitalization of $630.66 million, a price-to-earnings ratio of -5.04 and a beta of 0.89. Orthofix Medical has a 52 week low of $10.24 and a 52 week high of $20.73. The company has a quick ratio of 1.50, a current ratio of 2.67 and a debt-to-equity ratio of 0.38. The firm has a 50 day moving average of $14.77 and a 200 day moving average of $12.93.

Orthofix Medical (NASDAQ:OFIX) last issued its quarterly earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.40). The business had revenue of $203.12 million for the quarter, compared to analyst estimates of $196.89 million. Orthofix Medical had a negative return on equity of 25.43% and a negative net margin of 15.29%. Orthofix Medical has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Orthofix Medical will post -2.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Orthofix Medical

Several hedge funds have recently added to or reduced their stakes in the business. CWM LLC raised its position in shares of Orthofix Medical by 99.0% in the third quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock worth $28,000 after acquiring an additional 955 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Orthofix Medical by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock worth $335,000 after acquiring an additional 1,213 shares during the period. Gamco Investors INC. ET AL raised its position in shares of Orthofix Medical by 1.0% in the first quarter. Gamco Investors INC. ET AL now owns 157,100 shares of the medical device company’s stock worth $2,562,000 after acquiring an additional 1,500 shares during the period. State of Alaska Department of Revenue acquired a new position in shares of Orthofix Medical in the third quarter worth about $30,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Orthofix Medical by 21.1% in the second quarter. The Manufacturers Life Insurance Company now owns 14,867 shares of the medical device company’s stock worth $166,000 after acquiring an additional 2,589 shares during the period. 89.76% of the stock is owned by hedge funds and other institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.